By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novartis Pharmaceuticals Corporation 

One Health Plaza

East Hanover  New Jersey  07936-1080  U.S.A.
Phone: 973-781-8300 Fax: 973-781-8265



Vicuron Pharmaceuticals, Inc.  Deformylase and MUR: Pathway inhibitors for novel mechanism based antimicrobial drugs

Company News
Novartis Pharmaceuticals Corporation (NVS) Heart Failure Medicine Entresto Substantially Cuts 30-Day Hospital Readmissions, New Post-Hoc Analysis Shows 11/11/2015 6:53:39 AM
Novartis Pharmaceuticals Corporation (NVS) Release: Up to 80% Of ankylosing spondylitis Patients Treated With Cosentyx Show No Spinal X-Ray Progression As Shown In Novartis New Two-Year Observational Data 11/9/2015 11:14:41 AM
Approximately 80% Of Psoriatic Arthritis Patients Treated With Cosentyx Saw No Progression Of Joint Damage As Shown In Novartis Pharmaceuticals Corporation (NVS) New Two-Year Observational Data 11/9/2015 6:42:01 AM
Novartis Pharmaceuticals Corporation (NVS) Is First Company To Receive Number One Ranking Two Years In A Row On Diversityinc Top 50 Companies For Diversity List 4/27/2015 11:14:44 AM
Nine New Analyses Show Novartis Pharmaceuticals Corporation (NVS)' LCZ696 Could Change Course Of Heart Failure For Patients 11/17/2014 3:02:22 PM
Relapsing MS Patients More Satisfied With Novartis Pharmaceuticals Corporation (NVS) Oral Drug Gilenya┬« Than Standard Injectable Therapies, According to New Study Results at Consortium Service Management Group (CTUM.OB) 5/30/2013 6:39:55 AM
New Analysis Shows Novartis Pharmaceuticals Corporation (NVS) Drug Gilenya® Significantly Reduced Rate of Brain Volume Loss Across Three Large Phase III Studies 3/21/2013 10:34:29 AM
Novartis Pharmaceuticals Corporation (NVS) Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy 2/25/2013 10:38:43 AM
The New England Journal of Medicine Published Study Shows Novartis Pharmaceuticals Corporation (NVS) Compound ACZ885 Significantly Relieves Symptoms in Patients With Serious Form of Childhood Arthritis 12/20/2012 8:36:58 AM
Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation (NVS) for Up to $665 Million 9/19/2012 7:29:31 AM